plazomicin sold brand name zemdri aminoglycoside antibiotic used treat complicated urinary tract recommended alternatives given injection common side effects include kidney problems diarrhea nausea blood pressure severe side effects include hearing loss clostridium difficileassociated diarrhea anaphylaxis muscle use pregnancy may harm plazomicin works decreasing ability bacteria make plazomicin approved medical use united states world health organizations list essential plazomicin approved us food drug administration fda adults complicated urinary tract infections including pyelonephritis caused escherichia coli klebsiella pneumoniae proteus mirabilis enterobacter cloacae patients limited alternative treatment options zemdri intravenous infusion administered fda declined approval treating bloodstream infections due lack demonstrated lack demonstrated effectiveness much antibiotic ineffective much low enrollment rate study studies using mouse models however showed high survival plazomicin reported demonstrate vitro synergistic activity combined daptomycin ceftobiprole versus methicillinresistant staphylococcus aureus vancomycinresistant aureus pseudomonas aeruginosa combined cefepime doripenem imipenem also demonstrates potent vitro activity versus carbapenemresistant acinetobacter plazomicin found noninferior drug developed biotech company achaogen us food drug administration granted fast track designation development regulatory review fda approved plazomicin adults complicated utis limited alternative treatment options achaogen unable find robust market drug declared bankruptcy months generic version manufactured cipla derived sisomicin appending hydroxyaminobutyric acid substituent position hydroxyethyl substituent position latter makes impervious acetylation deactivation aminoglycoside acetyltransferase type ib prevalent aac plazomicin international nonproprietary name httpsenwikipediaorgwikiplazomicin